Paper-Nanjing Immunophage Biotech Co.,Ltd

CN

Paper
Patent

The Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Learn more
Discovery of a First-in-Class GPR183 Antagonist for the Potential Treatment of Rheumatoid Arthritis

Learn more
Discovery of a First-in-Class CD38 Inhibitor for the Treatment of Mitochondrial Myopathy

Learn more
Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer.

Learn more

1

上一页 1/1 下一页

About
Pipeline
- IPG1094 IPGA09
- IPG7236 IPGA06
- IPG0521 IPGA17
- IPG11406 IPG017
- IPG8294 IPG023
- IPG6620 IPGA12
Publications
- Paper
- Patent
News
- Press Release
- Media Reports
Careers
- Join Us

Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd

All Rights Reserved. 苏ICP备2022026466号-1 苏公网安备 32011202000830号